Chinook Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Chinook Therapeutics generated cash of -$117,481,000, which is less than the previous year. Cash used in financing activities reached the amount of $151,432,000 last year. Net change in cash is therefore -$66,286,000.
Cash Flow
| 2015 | 154.81M | -297.98M | 174.17M |
|---|---|---|---|
| 2016 | -86.07M | -32.53M | 43.08M |
| 2017 | -88.85M | 88.94M | 82.05M |
| 2018 | -68.75M | 39.40M | -1.49M |
| 2019 | -13.58M | -758K | 25.68M |
| 2020 | -55.84M | 109.67M | 124.29M |
| 2021 | -102.74M | -112.63M | 209.52M |
| 2022 | -117.48M | -99.99M | 151.43M |
KDNY Cash Flow Statement (2015 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 183.79M | 189.5M | 11.35M | 126.77M | 158.08M | 74.93M | 150.45M | 119.45M |
Operating activities | ||||||||
Net income | -187.86M | -102.93M | -81.62M | -46.51M | -95.35M | -91.86M | -91.14M | -39.20M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 5.09M | 4.75M | 1.43M | 221K | 4.95M | 3.98M | 2.55M | 723K |
Stock-based compensation expense | 20.05M | 12.78M | 3.61M | 95K | 17.47M | 16.37M | 15.00M | 8.43M |
| Deferred income tax benefit | 20.05M | 12.78M | 3.61M | 95K | 17.47M | 16.37M | 15.00M | 8.43M |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 8.97M | -9.79M | 818K | 11.69M | -11.04M | 149K | 3.70M | -1.69M |
Inventories | 0 | -515K | -9.22M | -11.69M | 0 | 0 | 0 | 0 |
Accounts payable | 1.38M | 4.54M | 553K | 283K | 533K | -1.20M | -2.85M | 1.53M |
Cash generated by operating activities | -117.48M | -102.74M | -55.84M | -13.58M | -68.75M | -88.85M | -86.07M | 154.81M |
Investing activities | ||||||||
Purchases Of Investments | -299.18M | -232.34M | -16.59M | -283.09M | -226.95M | -260.43M | -359.5M | -359.37M |
Investments In Property Plant And Equipment | -1.65M | -1.87M | -797K | -758K | -2.36M | -5.15M | -23.88M | -2.17M |
Acquisitions Net | 99.99M | 0 | 150K | 0 | 0 | 0 | 0 | -14.32M |
Cash generated by investing activities | -99.99M | -112.63M | 109.67M | -758K | 39.40M | 88.94M | -32.53M | -297.98M |
Financing activities | ||||||||
Common Stock Issued | 145.96M | 206.41M | 109.41M | 17K | 0 | 78.99M | 36.80M | 150.28M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -47K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 151.43M | 209.52M | 124.29M | 25.68M | -1.49M | 82.05M | 43.08M | 174.17M |
Net Change In Cash | -66.28M | -5.70M | 178.14M | -115.42M | -31.30M | 82.68M | -75.52M | 31M |
Cash at end of period | 117.51M | 183.79M | 189.5M | 11.35M | 126.77M | 157.61M | 74.93M | 150.45M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |